MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

How will regulatory change shape sponsor strategy in 2026? This end-of-year retrospective brings forward the themes that...
12/19/2025

How will regulatory change shape sponsor strategy in 2026? This end-of-year retrospective brings forward the themes that arose in recent industry conversations, including how sponsors can navigate a landscape driven by regulatory movement, tighter budgets, and higher data expectations.

Within the article, CEO Dr. Uma Sharma notes that “sponsors wanted thought and ex*****on partners who could help them align scientific, operational, and data-driven strategies in an unpredictable space. From our experience, regulatory flux made that alignment even more pressing.”

Read the full insights here and let us know what resonates most with you: https://hubs.li/Q03YfJSB0

AI is shaping clinical biometrics faster than anyone expected, and the conversations happening across data management, b...
12/17/2025

AI is shaping clinical biometrics faster than anyone expected, and the conversations happening across data management, biostatistics, and statistical programming show that teams are preparing for a very different future.

Our latest blog article recaps key insights shared by Satya Ingle at a 2025 PHUSE Single Day Event, including what AI singularity could mean for biometrics roles, workflows, and the skills teams will need to grow.

“One of the most important ideas is Symbiotic Intelligence, where AI accelerates production and humans guide strategy and interpretation. This balance helps teams grow capabilities that were not imagined before.”

If you are thinking about the future of biometrics or exploring how AI fits into your team’s work, this is worth a read: https://hubs.li/Q03YfQHn0

Celebrating Partnerships with PurposeAs 2025 draws to a close, we’re saying a heartfelt thank you to our clients and par...
12/16/2025

Celebrating Partnerships with Purpose

As 2025 draws to a close, we’re saying a heartfelt thank you to our clients and partners. To mark the season and our shared commitment to positive action, MMS has planted trees on behalf of our customers through https://hubs.li/Q03YhSWT0

Our roots run deep, and this gesture reflects our appreciation for our clients' trust and collaboration. Here’s to continued success together in 2026!

What will shape pharma and biotech the most in 2026? We spent time breaking down conversations and insights shared by MM...
12/16/2025

What will shape pharma and biotech the most in 2026? We spent time breaking down conversations and insights shared by MMS leaders to understand what influenced development decisions in 2025 and where sponsors see the strongest opportunities ahead.

One of the clearest industry-wide patterns was the dramatic rise in curiosity around AI. Leaders across pharma expressed a desire to innovate, yet many had limited clarity on how AI should be implemented. CIO Mohamad Zahreddine described the situation as, “an overwhelming wave that sometimes added fog instead of insight. Many organizations knew they needed AI but had no clear path for starting or scaling.”

Read the full insights here and let us know what resonates most with you: https://hubs.li/Q03YfHDs0

In 2025, MMS held numerous well-attended webinars throughout the year, covering a variety of topics that matter to clini...
12/15/2025

In 2025, MMS held numerous well-attended webinars throughout the year, covering a variety of topics that matter to clinical trial sponsors and partners worldwide. As we wrap up the year, these were a few of the key stand-outs in our list of most popular webinars:

▶️ A Practical Guide to Expedited Regulatory Pathways
▶️ The Psychedelic Inflection Point: What Sponsors Need to Know Now
▶️ De-Risking Development with Specialized Data Strategies: From Trial Design to Submission

Did you attend one of these? Let us know in the comments.

Weren’t able to attend? They’re all available on-demand here: https://hubs.li/Q03Y6H7J0

We are honored to have been named a finalist for Best CRO Specialist Provider at the Scrip Awards! Being shortlisted amo...
12/12/2025

We are honored to have been named a finalist for Best CRO Specialist Provider at the Scrip Awards! Being shortlisted among such prestigious peers confirms our commitment to strong science, data integrity, and service to sponsors and patients worldwide.

Congratulations to the winners and all finalists for continued innovation and dedication to advancing drug development!

At MMS we remain focused on delivering high-quality clinical research, regulatory support, and biometrics services that make a difference for clients and patients. Thank you to our team, our partners, and our clients for believing in our mission!

Read why we were shortlisted: https://hubs.li/Q03XYD-K0

Career growth in data management will be greater than 30% for the next few years, but to build and maintain a high-perfo...
12/11/2025

Career growth in data management will be greater than 30% for the next few years, but to build and maintain a high-performing team takes work! In a recent article, MMS data management leaders walk through what makes a data management team effective, including:

✅ Building trust across functions
✅ Maintaining quality at scale
✅ Applying technology thoughtfully
✅ Aligning data workflows with trial and regulatory needs

Read the full blog and learn what good data management looks like, and how to build it: https://hubs.li/Q03Xr8d70

Changing CROs mid-program or rescuing a troubled trial can feel like navigating a minefield. Have you experienced this? ...
12/09/2025

Changing CROs mid-program or rescuing a troubled trial can feel like navigating a minefield. Have you experienced this?

We understand that time is short, risk is high, and the pressure to deliver results is intense, and at MMS, we specialize in CRO transition and rescue services. We step in with experienced teams, deep operational know-how, and proven processes to stabilize, salvage, and accelerate trials when sponsors need it most.

Learn how MMS can help you turn a vulnerable trial into a managed, compliant, and delivery-ready program: https://hubs.li/Q03Xr90x0

Do you have questions about the EMA – Health Canada joint review process? MMS leaders break it down in our recent Perspe...
12/08/2025

Do you have questions about the EMA – Health Canada joint review process? MMS leaders break it down in our recent Perspectives article with four main takeaways and a discussion on how efficient the combined pathway really is for global sponsors.

We’ve seen as much as 70% of content overlap existed between the two submissions! Joint review like this can reduce redundancy and significantly accelerate timelines.

If you work on global submissions or plan to target both Europe and Canada, this overview helps you understand what’s changed, what works, and what you need to watch out for.

Read the full article: https://hubs.li/Q03Xd4tX0

With so much buzz around AI, it’s no surprise that sponsors are asking: “How are you using AI?” However, the better ques...
12/05/2025

With so much buzz around AI, it’s no surprise that sponsors are asking: “How are you using AI?” However, the better question might be: “How are you using AI to help me?”

At MMS, we approach these conversations by sharing perspective on where AI is currently valuable, like speeding up medical writing, anonymizing data, or supporting video review, for instance. We also make sure to discuss where the AI is still evolving, such as CRF development or automated statistical plan generation.

Read more and see what Sponsors really need from their CRO in terms of AI at https://hubs.li/Q03WQTGs0.

Breaking News: Former FDA, CRO, and industry leader Dr. Stephine Keeton has joined MMS as Senior Director of Biometrics!...
12/04/2025

Breaking News: Former FDA, CRO, and industry leader Dr. Stephine Keeton has joined MMS as Senior Director of Biometrics!

Chris Schoonmaker, Chief Operating Officer at MMS, shared, “Her appointment comes at an inflection point for our industry, as sponsors increasingly look for specialized partners who can guide them through complex data challenges and deliver high-quality, submission-ready results.”

Please give a warm welcome to Stephine in the comments, and read the entire announcement here: https://hubs.li/Q03WQ3qJ0

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.